Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gelesis Holdings's Revenue for the
three
months ended in Jun. 2023 was $1.11 Mil. Gelesis Holdings's average Accounts Receivable for the
three
months ended in Jun. 2023 was $1.04 Mil.
Hence, Gelesis Holdings's Receivables Turnover for the
three
months ended in Jun. 2023 was 1.07.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gelesis Holdings Receivables Turnover Related Terms
Gelesis Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Gelesis Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLSHQ vs RBSH, PPCB, RGMP: Receivables Turnover Comparison
For the Biotechnology subindustry, Gelesis Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelesis Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gelesis Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelesis Holdings (GLSHQ) has a Receivables Turnover of 1.07 as of Jun. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Receivables Turnover too high?
Gelesis Holdings' current Receivables Turnover is 1.07. The Biotechnology industry median Receivables Turnover is 5.29. Gelesis Holdings' value of 1.07 is 79.8% below this industry median.
How does Gelesis Holdings' Receivables Turnover compare to RBSH and PPCB?
Gelesis Holdings' Receivables Turnover of 1.07 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.29. Gelesis Holdings' value of 1.07 is 79.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gelesis Holdings's current Receivables Turnover of 1.07 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gelesis Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelesis Holdings's current Receivables Turnover is 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Receivables Turnover of 1.07. The current Receivables Turnover is 1.07 and 79.8% below the Biotechnology industry median of 5.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Receivables Turnover is 1.07 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLSHQ has been successfully added to your 
